BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 33171418)

  • 1. European consensus statement on essential colposcopy.
    Redman CWE; Kesic V; Cruickshank ME; Gultekin M; Carcopino X; Castro Sanchez M; Grigore M; Jakobsson M; Kuppers V; Pedro A; Reich O; Leeson S; Tabuica U; Zodzika J; Ciavattini A; Jach R; Katsyuba M; Koiss R; Martin-Hirsch P; Tjalma WA; Nieminen P;
    Eur J Obstet Gynecol Reprod Biol; 2021 Jan; 256():57-62. PubMed ID: 33171418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. European consensus statement on expert colposcopy.
    McGee AE; Alibegashvili T; Elfgren K; Frey B; Grigore M; Heinonen A; Jach R; Jariene K; Kesic V; Küppers V; Kyrgiou M; Leeson S; Louwers J; Mazurec M; Mergui J; Pedro A; Šavrova A; Siegler E; Tabuica U; Trojnarska D; Trzeszcz M; Turyna R; Volodko N; Cruickshank ME;
    Eur J Obstet Gynecol Reprod Biol; 2023 Nov; 290():27-37. PubMed ID: 37716200
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human papillomavirus test with cytology triage in organized screening for cervical cancer.
    Veijalainen O; Kares S; Kujala P; Tirkkonen M; Vuento R; Kholová I; Luukkaala T; Osuala V; Mäenpää J
    Acta Obstet Gynecol Scand; 2016 Nov; 95(11):1220-1227. PubMed ID: 27591407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Real-world research on cervical cancer screening program and effect evaluation for Chinese population].
    Zhao YQ; Dai Y; Dang L; Kong LH; Zhang Y; Feng RM; Qiao YL; Lang JH
    Zhonghua Zhong Liu Za Zhi; 2018 Oct; 40(10):764-771. PubMed ID: 30392341
    [No Abstract]   [Full Text] [Related]  

  • 5. The clinician's view: role of human papillomavirus testing in the American Society for Colposcopy and Cervical Pathology Guidelines for the management of abnormal cervical cytology and cervical cancer precursors.
    Cox JT;
    Arch Pathol Lab Med; 2003 Aug; 127(8):950-8. PubMed ID: 12952506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. European guidelines for quality assurance in cervical cancer screening: recommendations for clinical management of abnormal cervical cytology, part 1.
    Jordan J; Arbyn M; Martin-Hirsch P; Schenck U; Baldauf JJ; Da Silva D; Anttila A; Nieminen P; Prendiville W
    Cytopathology; 2008 Dec; 19(6):342-54. PubMed ID: 19040546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of Cervical Dysplasia After Colposcopy Care and Risk-Informed Return to Population-Based Screening: A Systematic Review.
    Costa-Fagbemi M; Yakubu M; Meggetto O; Moffatt J; Walker MJ; Koné AP; Murphy KJ; Kupets R
    J Obstet Gynaecol Can; 2020 May; 42(5):607-624. PubMed ID: 31679914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of a high-risk human papillomavirus DNA test as the primary test in a cervical cancer screening programme: a population-based cohort study.
    Zorzi M; Del Mistro A; Farruggio A; de'Bartolomeis L; Frayle-Salamanca H; Baboci L; Bertazzo A; Cocco P; Fedato C; Gennaro M; Marchi N; Penon MG; Cogo C; Ferro A
    BJOG; 2013 Sep; 120(10):1260-7; discussion 1267-8. PubMed ID: 23786222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection Rate of High-Grade Cervical Neoplasia and Cost-Effectiveness of High-Risk Human Papillomavirus Genotyping with Reflex Liquid-based Cytology in Cervical Cancer Screening.
    Tay SK; Lin LE; Goh RC
    Ann Acad Med Singap; 2017 Jul; 46(7):267-273. PubMed ID: 28821890
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The IMproving Primary Screening And Colposcopy Triage trial: human papillomavirus, cervical cytology, and histopathologic results from the baseline and 1-year follow-up phase.
    Safaeian M; Wright TC; Stoler MH; Ranger-Moore J; Rehm S; Aslam S; Fang Q; Volkir P; Ridder R
    Am J Obstet Gynecol; 2021 Sep; 225(3):278.e1-278.e16. PubMed ID: 33852886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Health technology assessment report: HPV DNA based primary screening for cervical cancer precursors].
    Ronco G; Biggeri A; Confortini M; Naldoni C; Segnan N; Sideri M; Zappa M; Zorzi M; Calvia M; Accetta G; Giordano L; Cogo C; Carozzi F; Gillio Tos A; Arbyn M; Mejier CJ; Snijders PJ; Cuzick J; Giorgi Rossi P
    Epidemiol Prev; 2012; 36(3-4 Suppl 1):e1-72. PubMed ID: 22828243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A pilot study of HPV DNA and cytology testing in 50,159 women in the routine Mexican Social Security Program.
    Lazcano-Ponce E; Lörincz AT; Salmerón J; Fernández I; Cruz A; Hernández P; Mejia I; Hernández-Avila M
    Cancer Causes Control; 2010 Oct; 21(10):1693-700. PubMed ID: 20617376
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-risk HPV testing in women with borderline and mild dyskaryosis: long-term follow-up data and clinical relevance.
    Denise Zielinski G; Snijders PJ; Rozendaal L; Voorhorst FJ; Runsink AP; de Schipper FA; Meijer CJ
    J Pathol; 2001 Oct; 195(3):300-6. PubMed ID: 11673826
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Benefits and potential harms of human papillomavirus (HPV)-based cervical cancer screening: A real-world comparison of HPV testing versus cytology.
    Thomsen LT; Kjaer SK; Munk C; Ørnskov D; Waldstrøm M
    Acta Obstet Gynecol Scand; 2021 Mar; 100(3):394-402. PubMed ID: 33566361
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.
    Castle PE; Stoler MH; Wright TC; Sharma A; Wright TL; Behrens CM
    Lancet Oncol; 2011 Sep; 12(9):880-90. PubMed ID: 21865084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting.
    Leinonen M; Nieminen P; Kotaniemi-Talonen L; Malila N; Tarkkanen J; Laurila P; Anttila A
    J Natl Cancer Inst; 2009 Dec; 101(23):1612-23. PubMed ID: 19903804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk-adapted primary HPV cervical cancer screening project in Wolfsburg, Germany--experience over 3 years.
    Luyten A; Scherbring S; Reinecke-Lüthge A; Braun BE; Pietralla M; Theiler K; Petry KU
    J Clin Virol; 2009 Nov; 46 Suppl 3():S5-10. PubMed ID: 20129072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical value of p16
    Song FB; Du H; Xiao AM; Wang C; Huang X; Yan PS; Liu ZH; Qu XF; Belinson JEROMEL; Wu RF
    Zhonghua Fu Chan Ke Za Zhi; 2020 Nov; 55(11):784-790. PubMed ID: 33228350
    [No Abstract]   [Full Text] [Related]  

  • 19. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
    C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
    Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary HPV cervical screening: Clinical audit of outcomes of women seen at a tertiary referral centre for colposcopy in Australia.
    Chin FHX; Wrede CDH; Richards A; Steele A; Vicario E; McNally OM; Tan JHJ
    Aust N Z J Obstet Gynaecol; 2021 Oct; 61(5):750-758. PubMed ID: 33963546
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.